AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma ("MCL"), double-hit lymphoma ("DHL") and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern existing composition-of-matter patent estate. Lantern Pharma (NASDAQ: LTRN) is evaluating LP-284 in an ongoing Phase 1a…